Cargando…
A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations
Radiotherapy has proven efficacy in a wide range of cancers. There is growing interest in evaluating radiotherapy–novel agent combinations and a drive to initiate this earlier in the clinical development of the novel agent, where the scientific rationale and preclinical evidence for a radiotherapy c...
Autores principales: | Brown, Sarah R., Hinsley, Samantha, Hall, Emma, Hurt, Chris, Baird, Richard D., Forster, Martin, Scarsbrook, Andrew F., Adams, Richard A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433953/ https://www.ncbi.nlm.nih.gov/pubmed/35552622 http://dx.doi.org/10.1158/1078-0432.CCR-21-4087 |
Ejemplares similares
-
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
por: Walls, Gerard M., et al.
Publicado: (2020) -
Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE
por: Walker, Katrina, et al.
Publicado: (2022) -
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS
por: Gollins, Simon, et al.
Publicado: (2018) -
Genetic heterogeneity in breast cancer: the road to personalized medicine?
por: Baird, Richard D, et al.
Publicado: (2013) -
Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples
por: van Werkhoven, Erik, et al.
Publicado: (2020)